IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-55002-6.html
   My bibliography  Save this article

Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population

Author

Listed:
  • Stefan Wolf

    (University Hospital Zurich, University of Zurich)

  • Matiar Madanchi

    (University Hospital Zurich, University of Zurich)

  • Patrick Turko

    (University Hospital Zurich, University of Zurich
    University Hospital Zurich, University of Zurich)

  • Maija Hollmén

    (University of Turku)

  • Sonia Tugues

    (University of Zurich)

  • Julia Atzigen

    (University Hospital Zurich, University of Zurich)

  • Pietro Giovanoli

    (University Hospital Zurich, University of Zurich)

  • Reinhard Dummer

    (University Hospital Zurich, University of Zurich)

  • Nicole Lindenblatt

    (University Hospital Zurich, University of Zurich)

  • Cornelia Halin

    (ETH Zurich)

  • Michael Detmar

    (ETH Zurich)

  • Mitchell Levesque

    (University Hospital Zurich, University of Zurich)

  • Epameinondas Gousopoulos

    (University Hospital Zurich, University of Zurich)

Abstract

Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4+T cells influences lymphedema onset and emerges as a promising therapy target. Here, we show that the modulation of CD4+FOXP3+CD25+regulatory T (Treg) cells upon anti-CTLA4 treatment protects against lymphedema development in patients with melanoma and in a mouse lymphedema model. A retrospective evaluation of a melanoma patient registry reveals that anti-CTLA4 reduces lymphedema risk; in parallel, anti-CTLA4 reduces edema and improves lymphatic function in a mouse-tail lymphedema model. This protective effect of anti-CTLA4 correlates with a systemic expansion of Tregs, both in the animal model and in patients with melanoma. Our data thus show that anti-CTLA4 with its lymphedema-protective and anti-tumor properties is a promising candidate for more diverse application in the clinics.

Suggested Citation

  • Stefan Wolf & Matiar Madanchi & Patrick Turko & Maija Hollmén & Sonia Tugues & Julia Atzigen & Pietro Giovanoli & Reinhard Dummer & Nicole Lindenblatt & Cornelia Halin & Michael Detmar & Mitchell Leve, 2024. "Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-55002-6
    DOI: 10.1038/s41467-024-55002-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-55002-6
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-55002-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Nicola Nosengo, 2016. "Can you teach old drugs new tricks?," Nature, Nature, vol. 534(7607), pages 314-316, June.
    2. Jason C. Gardenier & Raghu P. Kataru & Geoffrey E. Hespe & Ira L. Savetsky & Jeremy S. Torrisi & Gabriela D. García Nores & Dawit K. Jowhar & Matthew D. Nitti & Ryan C. Schofield & Dean C. Carlow & Ba, 2017. "Topical tacrolimus for the treatment of secondary lymphedema," Nature Communications, Nature, vol. 8(1), pages 1-11, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Thaila Fernanda Reis & Patrícia Alves Castro & Rafael Wesley Bastos & Camila Figueiredo Pinzan & Pedro F. N. Souza & Suzanne Ackloo & Mohammad Anwar Hossain & David Harold Drewry & Sondus Alkhazraji &, 2023. "A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    2. Shin, Hyunjin & Woo, Hyun Goo & Sohn, Kyung-Ah & Lee, Sungjoo, 2023. "Comparing research trends with patenting activities in the biomedical sector: The case of dementia," Technological Forecasting and Social Change, Elsevier, vol. 195(C).
    3. Kouichi Hosomi & Mai Fujimoto & Kazutaka Ushio & Lili Mao & Juran Kato & Mitsutaka Takada, 2018. "An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-19, October.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-55002-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.